Subthreshold laser for retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old
- You must have a confirmed diagnosis of retinitis pigmentosa (RP) based on eye exam, vision tests, and genetic testing
- Your best corrected vision must be at least 20/250 (Snellen) in at least one eye
- You cannot have other serious eye diseases like glaucoma or macular degeneration
- You cannot have had eye surgery (except uncomplicated cataract surgery) in the past 3 months
- You cannot use other RP treatments or immune-modulating medications during the study or for 3 months before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
This trial tests a new form of the drug pitavastatin, which is usually used for cholesterol, but here it's given as tiny particles injected into the eye. The goal is to see if it's safe and might help people with retinitis pigmentosa, a condition that causes vision loss.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
Hear when a new Retinitis Pigmentosa (RP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.